---
title: "在诺华以 120 亿美元收购竞争对手 Avidity 的交易后，PepGen 和 Dyne 股价上涨"
description: "PepGen 的股价上涨 21%，达到 5.53 美元，而 Dyne Therapeutics 则飙升 37.5%，达到 23.54 美元，此次涨幅是由于诺华以 120 亿美元收购 Avidity Biosciences。两家公司都在开发针对罕见肌肉疾病的治疗方案。RBC 资本市场预测，由于 Dyne 与 Avidity 拥有相似的平台，其股价将显著上涨，Avidity 的市值为 24 亿美元。今"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262933544.md"
published_at: "2025-10-27T15:24:34.000Z"
---

# 在诺华以 120 亿美元收购竞争对手 Avidity 的交易后，PepGen 和 Dyne 股价上涨

> PepGen 的股价上涨 21%，达到 5.53 美元，而 Dyne Therapeutics 则飙升 37.5%，达到 23.54 美元，此次涨幅是由于诺华以 120 亿美元收购 Avidity Biosciences。两家公司都在开发针对罕见肌肉疾病的治疗方案。RBC 资本市场预测，由于 Dyne 与 Avidity 拥有相似的平台，其股价将显著上涨，Avidity 的市值为 24 亿美元。今年至今，Dyne 上涨了 1.8%，而 PepGen 则增长了 47.8%

制药公司 PepGen（PEPG.O）股价上涨 21%，至 5.53 美元，而 Dyne Therapeutics（DYN.O）上涨 37.5%，至 23.54 美元。竞争对手 Avidity Biosciences（RNA.O）周日同意被瑞士制药公司诺华（Novartis，NOVN.S）以约 120 亿美元现金收购，以增强其稀有肌肉疾病治疗产品组合。

Pepgen 和 Dyne 目前也在开发治疗稀有肌肉疾病的药物，例如肌强直性营养不良症 1 型。

“我们预计 DYN 明天的交易价格将大幅上涨，因为其平台与 RNA 相似，且市值并未落后于 RNA，约为 24 亿美元。”- RBC 资本市场。

包括本次交易的变动，DYN 上涨 1.8%，PEPG 年初至今上涨 47.8%。

### Related Stocks

- [DYN.US - Dyne Therapeutics](https://longbridge.com/zh-CN/quote/DYN.US.md)
- [PEPG.US - PepGen](https://longbridge.com/zh-CN/quote/PEPG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| PepGen (PEPG) Expected to Announce Earnings on Monday | PepGen (NASDAQ:PEPG) is set to announce its Q4 2025 earnings on February 23, with analysts predicting a loss of $0.38 pe | [Link](https://longbridge.com/zh-CN/news/276043198.md) |
| Dyne Therapeutics: Positioned for Growth in the RNA Therapeutics Market Amid Industry Validation | Francois Brisebois has issued a Buy rating for Dyne Therapeutics, citing the recent $12 billion acquisition of Avidity B | [Link](https://longbridge.com/zh-CN/news/262941348.md) |
| Significant opportunities exist in the global pain market for novel mechanisms and modalities | The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alter | [Link](https://longbridge.com/zh-CN/news/275921122.md) |
| Circio Grants Broad Employee Stock Options After NOK 70m Fundraise | Circio Holding ASA has launched a stock option program for employees, issuing 5 million options after raising NOK 70 mil | [Link](https://longbridge.com/zh-CN/news/275972910.md) |
| Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A. | Candriam S.C.A. increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA) by 10.2% in Q3, owning 487,917 shares valu | [Link](https://longbridge.com/zh-CN/news/275451342.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。